32 results about "Streptococcal M protein" patented technology

This application discloses a circular RNA vaccine against porcine reproductive and respiratory syndrome (PRRS) virus, its construction method, and its application. The circular RNA vaccine comprises circular RNA and a pharmaceutically acceptable carrier. The coding elements in the circular RNA encode the GP4, GP2, GP5, and M proteins of PRRS virus. The circular RNA vaccine exhibits high stability and good safety, producing no adverse reactions after immunization of pigs. It induces high levels of neutralizing antibodies in pigs after immunization and activates a high level of cellular immune response, providing up to 100% immunoprotection. Furthermore, its preparation process eliminates the need for virus isolation, significantly shortening the research and development cycle. The production process is not constrained by biological factors such as virus titer, facilitating standardization and large-scale production, and effectively reducing production costs.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.

This invention provides a broad-spectrum mRNA vaccine for the prevention of feline infectious peritonitis (FIP) and its preparation method. The vaccine comprises mRNA molecule 1 and mRNA molecule 2. mRNA molecule 1 contains an LS-FIPV-I MEV-N-M antigen protein coding sequence composed of a self-assembled LS nanoparticle fusion sequence based on a tandem neutralizing epitope of the FIPV type I S protein and a T-cell epitope, as well as antigen-coding sequences of the N and M proteins. mRNA molecule 2 contains an antigen protein coding sequence of an LS nanoparticle structure self-assembled from the FIPV type II S protein receptor domain RBD. This invention, through the combination of two mRNA molecules, can achieve broad-spectrum protection against both FIPV types I and II while mitigating the risk of adverse drug reaction (ADE).

The invention discloses an engineered exosome of LTH peptide modified miR-146a-5p and application, the core component of the medicine is the engineered exosome, and the engineered exosome is constructed by the following method: miR-146a-5p mimic infected human renal tubular epithelium HK2 cells with nucleotide sequences shown as SEQ ID NO.1-SEQ ID NO.2 are cultured and screened, the exosome rich in miR-146a-5p is separated from the culture supernatant of the cells, and the exosome rich in miR-146a-5p is obtained. Then, the kidney targeting peptide LTH is modified on the surface of the exosome. The invention reveals that HNRNP M protein is a key molecule for regulating and controlling miR-146a-5p to be sorted and enter the exosome for the first time, and verifies that the engineered exosome can be efficiently enriched in kidney, and by delivering miR-146a-5p to target IRAK1 gene in macrophage and inhibiting TRAF6 / IKK / NF-kappa B inflammation signal pathway, the macrophage is promoted to be polarized to a repairable M2 phenotype, so as to realize the purpose of improving the activity of the miR-146a-5p. And finally, the kidney injury induced by the calcium oxalate crystal is effectively relieved. The medicine has the advantages of clear mechanism, strong targeting property, good biocompatibility and the like, provides a brand new immunoregulation treatment strategy for renal injury, and has a wide clinical application prospect.

The invention relates to a multiplex fluorescent quantitative PCR (polymerase chain reaction) detection method for streptococcus equi subsp. Zooepidemicus virulent strains causing swine streptococcosis, and belongs to the technical field of bacterial detection. The invention provides a primer probe group which can be used for simultaneously detecting M protein variable region genes (szm-variant) of streptococcus equi subsp.zooepidemicus, conserved genes (comB) in subsp.zooepidemicus and central nervous system infection related virulence genes (bifA) of streptococcus equi subsp.zooepidemicus through Taqman probe triple fluorescent quantitative PCR (Polymerase Chain Reaction), and is shown as SEQ ID NO.1-9 in a sequence table. The multiplex fluorescent quantitative PCR detection method for the streptococcus equi subsp. Zooepidemicus virulent strain causing the swine streptococcosis can complete nucleic acid amplification and result judgment within 1 hour. According to the detection method, the amplification result is judged through the threshold cycle number (Ct value), electrophoresis detection is not needed, and the problems of pollution, false positive and the like of an amplification product can be avoided. The detection method provided by the invention has the characteristics of simplicity, convenience and rapidness in operation, high specificity, high sensitivity and good stability.

The invention discloses application of carfilzomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of nipah virus M protein, the carfilzomib is used for inhibiting a host proteasome path, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and the effect is good. At present, most of research and development of virus medicines and vaccines are designed or modified aiming at viruses, a new thought is provided for research and development of medicines and vaccines in the future, and a new application is also provided for Carfilzomib.

The invention discloses an anti-metapneumovirus M protein antibody and a derivative product and application thereof, the antibody is 7D4 or 5B8 and has high affinity and specificity to metapneumovirus M protein, and the derivative product comprises a detection reagent, a detection kit, a detection chip, a detection test strip and the like. The invention provides a new thought and strategy for early diagnosis or screening of metapneumovirus infection diseases.

Disclosed is a method for treatment of a tumor by using a recombinant oncolytic virus in combination with a small-molecule anticancer drug. Specifically, the method includes the following steps: treating the tumor by using the recombinant oncolytic virus in combination with the small-molecule anticancer drug, wherein the small-molecule anticancer drug includes a small-molecule anticancer drug targeting ALK, a small-molecule anticancer drug targeting BTK, a small-molecule anticancer drug targeting EGFR, a small-molecule anticancer drug targeting FGFR, a small-molecule anticancer drug targeting HER2, a small-molecule anticancer drug targeting Parp, a small-molecule anticancer drug targeting PI3K, a small-molecule anticancer drug targeting VEGFR, a small-molecule anticancer drug targeting CDK4 / 6, and a small-molecule anticancer drug targeting KRAS; and the recombinant oncolytic virus comprises an M protein, a G protein, an N protein, a P protein, and an L protein after site-directed mutagenesis.

This disclosure relates to the development of a multi-antigen mRNA vaccine against feline infectious peritonitis virus (FIPV). Provided is a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is mRNA and includes at least one of a first nucleic acid fragment, a second nucleic acid fragment, or a third nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; the third nucleic acid fragment encodes an S protein, an S_ec protein, or an SII protein of feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment, and the third nucleic acid fragment are linked or not linked.

The invention discloses a metapneumovirus M protein antibody and application thereof. The amino acid sequences of the complementary determining regions of the heavy chain variable region and the light chain variable region of the metapneumovirus M protein antibody provided by the invention are clear and are respectively shown as SEQ ID NO: 1-8, and the metapneumovirus M protein antibody has relatively high affinity and specificity to the metapneumovirus M protein. The metapneumovirus M protein antibody disclosed by the invention can effectively avoid cross reaction and remarkably improve the accuracy and sensitivity of detection, is suitable for early antigen detection of metapneumovirus infection, provides a reliable technical means for screening of metapneumovirus and prevention and control of diseases, and has a wide clinical application prospect.

Provided herein are methods of immunizing against, treating or preventing streptococcal toxic shock syndrome in a subject, by administration of a group A streptococcus M protein, inclusive of fragments, variants or derivatives thereof, or an antibody that binds, or is raised against the M protein and optionally a group A streptococcus superantigen protein, inclusive of fragments, variants or derivatives thereof, or an antibody or antibody fragment that binds, or is raised against, the superantigen protein.

The application provides a method for soluble expression and purification of recombinant human interleukin-2 or / and mutants thereof in a prokaryotic system, which utilizes a method for tandem fusion of two or more Sumo sequences, realizes soluble expression of human IL-2 in an E. coli expression system, avoids formation of inclusion bodies of IL-2 expressed by a traditional E. coli system, avoids expression of IL-2 and IL-2M in the form of inclusion bodies without structure and activity, avoids a process of IL-2 protein renaturation in the downstream, and realizes efficient purification of rhIL-2 and IL-2M proteins from a complex bacterial broken supernatant system through a simple chromatography step. The method has the characteristics of simple operation, suitability for scale-up, short cycle, high purity, stable process and the like.

The invention discloses a biomarker related to aortic dissection, a kit, a system and application thereof, and relates to the technical field of biological medicine. The biological marker related to the aortic dissection comprises a second biological marker; the second biomarker is used for predicting the clinical death risk of aortic dissection patients, and the second biomarker comprises SYTL1 protein, B2M protein, LYVE1 protein, TTR protein, PRSS2 protein, CSTF1 protein and H2BC5 protein. The plasma-based protein biomarker capable of predicting the mortality risk of the aortic dissection patient is successfully screened out, the pathogenesis of the disease can be explored easily, and the method has important significance on efficient, accurate and low-cost diagnosis of the aortic dissection patient.

The present invention is a hybridoma cell line for secreting monoclonal antibody against rabies virus M protein and its application, relates to the field of biotechnology. A classification of the hybridoma cell line is named as hybridoma cell line 4A1, and the hybridoma cell line was deposited on Apr. 1, 2019 in the China Center for Type Culture Collection, Wuhan University, Wuhan, China, with a deposit number CCTCC NO: C201947. The monoclonal antibody prepared by the hybridoma cell line has high titer, good specificity and excellent biological characteristics. The present invention identifies the variant antigen epitope recognized by the RABV M protein, the hybridoma cell line can be used to distinguish Flury strain and other RABV strains, prepare kit for detecting rabies virus RABV, detect RABV infection and differential diagnosis vaccine Flury strain and other RABV strains.

The invention relates to the technical field of veterinary biological products, and discloses a porcine reproductive and respiratory syndrome virus (PRRSV) genetic engineering subunit vaccine and a preparation method and application thereof, the vaccine comprises a PRRSV ZJ266 GP5-M protein complex and an adjuvant, and the adjuvant is a mannose modified chitosan solution. The PRRSV ZJ266 GP5-M protein compound is formed by GP5 protein and M protein of a PRRSV ZJ266 strain expressed and purified by a Bac-to-Bac baculovirus expression system, the nucleotide sequence of the PRRSV ZJ266 GP5-M protein compound is shown as SEQ ID NO: 1, and the amino acid sequence of the PRRSV ZJ266 GP5-M protein compound is shown as SEQ ID NO: 2. According to the invention, a high-level neutralizing antibody can be induced to generate, 100% protection is provided for attack of PRRSV NADC30-like virulent strains, the virus load can be significantly reduced, and detoxification can be prevented. The vaccine provided by the invention is safe and effective, the preparation process is stable, and a new high-quality product choice is provided for preventing the PRRSV.

This invention relates to the field of biotechnology, and particularly to a PRRSV-GP3-GP5-M+PCV2-TBCap recombinant protein, a vaccine, and its applications. This invention successfully expresses PRRSV GP5, GP3, and M proteins and PCV2TBCap protein using a cyclovir expression system. This recombinant protein can induce a favorable humoral and cellular immune response in the body, exhibiting good immunogenicity and safety.

Disclosed are compositions and methods for vaccinating susceptible individuals against infection by respiratory syncytial virus (RSV). The disclosed compositions include vaccine compositions comprising an effective amount of respiratory syncytial virus (RSV) F protein in a pre-fusion stabilized form and / or M protein incorporated into biodegradable polyanhydride polymer particles for inducing an immune response against RSV. The vaccine compositions also may include a suitable adjuvant.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to fusion protein and nanoparticles of porcine reproductive and respiratory syndrome virus recombinant epitopes and application of the fusion protein and the nanoparticles. A GP3 protein antigen epitope, a GP4 protein antigen epitope, a GP5 protein antigen epitope and an M protein antigen epitope are recombined, the obtained recombinant protein is closely related to protective immunity of the PRRSV, a strong humoral immune response aiming at the PRRSV can be generated after piglets are immunized, and a good protection effect is generated on infection of the PRRSV. The fusion protein is connected with the beta-cyclopeptide, and the beta-cyclopeptide serving as a nano skeleton can spontaneously form 24-surface nanoparticles, so that the antigen can be effectively presented, and the immune effect of the vaccine is promoted. Furthermore, the N terminal of the beta cyclopeptide is connected with an OX40L protein, and the OX40L protein belongs to a tumor necrosis factor ligand superfamily, so that the cellular immune effect can be further improved.

This invention relates to the preparation and application of a recombinant bivalent vaccine for porcine reproductive and respiratory syndrome (PRRS). The recombinant bivalent PRRS vaccine is prepared using gene recombination technology. The genes encoding the fusion proteins of the major structural proteins GP2, GP3, GP4, GP5, and M protein B-cell epitopes of PRRS-like strains NADC30 and NADC34, as well as their recombinant strains, are cloned into a vector, transformed into host bacteria, and prepared through processes such as fermentation, purification, mixing, and emulsification. Animal experiments show that the recombinant bivalent PRRS vaccine can effectively improve the humoral and cellular immune responses in target animals.

The invention provides a method for constructing circular RNA (Ribonucleic Acid) and a vaccine aiming at the cat FIPV. The method relates to a pharmaceutical preparation, the pharmaceutical preparation comprises nucleic acid fragments, the nucleic acid fragments are circular RNA, and the nucleic acid fragments comprise a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encodes M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes N protein of feline infectious peritonitis virus; the first nucleic acid fragment and the second nucleic acid fragment are connected or not connected.

The invention provides a broad-spectrum mRNA vaccine for preventing feline infectious peritonitis and a preparation method thereof, the vaccine comprises an mRNA molecule 1 and an mRNA molecule 2, the mRNA molecule 1 comprises a self-assembled LS nanoparticle fusion sequence based on a neutralizing epitope of series FIPV type I S protein and a T cell epitope, and the mRNA molecule 2 comprises a self-assembled LS nanoparticle fusion sequence based on series FIPV type I S protein. The LS-FIBV-I MEV-N-M antigen protein coding sequence is composed of the antigen coding sequences of the N protein and the M protein; the mRNA molecule 2 comprises an antigen protein coding sequence which is fused and self-assembled by an FIPV II type S protein receptor structural domain RBD and has an LS nano-particle structure. According to the invention, through the combination of double mRNA molecules, while the ADE risk is avoided, the broad-spectrum protection of the FIPV type I and the FIPV type II is realized.

To provide an antibody that can distinguish between a therapeutic antibody and an endogenous antibody and avoid interference caused by the therapeutic antibody during SPEP and IFE.SOLUTION: Provided is an anti-idiotypic antibody fused to human albumin.SELECTED DRAWING: None

Provided is a method for constructing a circular RNA and a vaccine against a feline infectious peritonitis virus (FIPV). The present method relates to a pharmaceutical formulation. The pharmaceutical formulation includes a nucleic acid fragment. The nucleic acid fragment is a circular RNA and includes a first nucleic acid fragment and a second nucleic acid fragment. The first nucleic acid fragment encodes an M protein of feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of feline infectious peritonitis virus; and the first nucleic acid fragment and the second nucleic acid fragment are linked or not linked. The pharmaceutical formulation against feline infectious peritonitis virus prepared by the method of the present disclosure has advantages such as a good immune efficacy, a simple preparation process, high safety, no toxic and side effects, and industrial producibility.

The present application relates to the technical field of biological detection, and particularly relates to a total bilirubin detection kit resisting high M protein interference. The total bilirubin detection kit resisting high M protein interference provided by the present application prevents the sample from being interfered in the detection process by adding a solubilizing dispersing agent and removing metal ions, optimizes the reagent components, and effectively avoids and reduces the interference of high M protein on the sample detection process. The solubilizing dispersing agent is added in the determination reagent while the ion concentration is reduced, the phenomenon of aggregation and precipitation in the detection process of the high M protein sample is eliminated, the detection process is no longer interfered, and the accuracy of the detection of the sample is improved.

Provided are modified alpha-2-macroglobulin (A2M) proteins with altered binding to clearance receptors such as LRP1 and GRP78, compositions comprising protein complexes of the modified A2M proteins with serine protease proteins such as porcine pancreatic elastase (PPE), compositions comprising protein complexes of alpha-2-macroglobulin-like protein 1 (A2ML1) with serine protease proteins, and related methods of use and manufacture for treating diseases such as cancers.

This invention discloses an antibody that specifically binds to the metapneumovirus M protein, along with related products and uses, including its amino acid sequence, encoding nucleic acid, expression vector, recombinant host cell, antibody derivative, and preparation method. Experiments have confirmed that the antibody exhibits high expression levels and purity in mammalian cells, binds to the target protein with high affinity and high specificity, and shows no cross-reactivity with various common respiratory viruses and the metapneumovirus N protein. It is suitable for developing diagnostic kits, test strips, chips, and other detection products for metapneumovirus infection, with broad application prospects.

The invention discloses application of ixazomib in preparation of a medicine for preventing and treating Nipah virus, and belongs to the technical field of medicine. The method mainly aims at ubiquitination modification of the nipah virus M protein, the host proteasome pathway is inhibited through the ixazomib, free ubiquitination factors in cells are depleted to achieve the effect of inhibiting ubiquitination of the M protein, then nucleoplasm shuttle of the M protein is inhibited, replication of the nipah virus is inhibited, and a good effect is achieved. The ixazomib is used as a nipah virus inhibitor, belongs to a new application of an old medicine, and provides a new application for the ixazomib. And the safety of the ixazomib has no problem, so that the ixazomib can be applied clinically. In addition, at present, most of research and development of virus drugs and vaccine research are designed or modified aiming at viruses, and a new thought is provided for research and development of drugs and vaccines in the future.

The invention discloses a CRISPR-Cas12m (clustered regularly interspaced short palindromic repeats) system and application thereof, and relates to the technical field of biological medicines. The CRISPR-Cas system is a CRISPR-Cas12m system and comprises a Cas12m polypeptide, and the amino acid sequence of the Cas12m polypeptide is as follows: (1) the amino acid sequence of the Cas12m polypeptide is shown as any one of SEQ ID NO.1-21; and (2) compared with the sequence as shown in SEQ ID NO.1-21, the sequence has 70% of sequence identity. The molecular weight of the Cas12m protein is small, in-vivo delivery is facilitated, and the protein has DNA binding activity and does not have DNA cleavage activity. The protein can be combined with an adenosine deaminase structural domain to form a base editor, and can also be combined with a transcriptional regulation structural domain to form an epigenetic editor.

The application discloses a specific T cell epitope peptide screened by a whole proteome of S1, N and M proteins of a novel coronavirus and application, relates to the technical field of biological medicine, and its technical points are: the application provides a plurality of CD4+ T and CD8+ T cell epitope polypeptides of the novel coronavirus, and the genes, recombinant proteins or complexes containing the epitope polypeptides, sensitized antigen presenting cells and specific immune effector cells for the epitope polypeptides are used in the development of a novel coronavirus vaccine and the treatment of diseases.The polypeptide provided by the application is screened from the peripheral blood sample of a recovered person who breaks through infection of Omicron BA.5 after inactivated vaccine booster vaccination, and can safely and effectively induce CD4+ T and CD8+ T cell immune responses to the novel coronavirus protein, and has important guiding significance for the development of a novel coronavirus vaccine.

The application discloses a capillary serum protein electrophoresis atlas partition method, device, medium and equipment, and belongs to the M protein analysis field. The application firstly acquires a serum protein electrophoresis curve of M protein and performs effectiveness judgment, calculates a candidate peak group of the serum protein electrophoresis curve and an abscissa position of the candidate peak group after the effectiveness judgment passes, then determines three candidate regions according to the number and the abscissa position of the candidate peak group, and calculates the ordinate minimum value of the three candidate regions and corresponding abscissa positions fl, sl and tl, and determines the beta region and the gamma region according to the abscissa positions fl, sl and tl. The application can automatically divide the beta region and the gamma region of a serum protein electrophoresis control atlas according to the serum protein electrophoresis curve, is more intelligent and efficient, and does not need manual adjustment, and when analyzing a complex serum protein electrophoresis control atlas, the beta region and the gamma region can be more accurately divided.